Search results
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
Investor's Business Daily· 6 days agoAvidity Biosciences unveiled "impressive" results from a study of its treatment for a rare form of ...
FDA approves generic Emflaza oral suspension for Duchenne muscular dystrophy
Medical Xpress· 1 day agoThe U.S. Food and Drug Administration has approved the first generic version of Emflaza...
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
BioPharma Dive via Yahoo Finance· 6 days agoStudy results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open
Barrons.com· 5 days agoThe drug company Pfizer said a gene therapy it is testing failed to improve motor function in boys...
$10,000 for 10 years: Chesterfield-based organization helping those with neuromuscular disorders
WRIC 8 News Richmond· 6 days agoFor ten years, the Colorado Fund for Muscular Dystrophy (CMFD) has been working to improve the lives...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with...
Morningstar· 6 days agoThe primary endpoint in the final analysis was assessed by change in the North Star Ambulatory...
...Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living...
Morningstar· 6 days agoAvidity plans to accelerate initiation of registrational cohorts in the FORTITUDE™ study.
Early data for Avidity's RNA therapy show possible functional benefit in muscular dystrophy
FierceBiotech· 6 days agoAvidity Biosciences’ AOC 1020, newly dubbed del-brax, demonstrated a safe profile and was tied to...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 6 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical company ...
Sarepta’s stock gains after Pfizer’s Duchenne trial failure - Boston Business Journal
The Business Journals· 5 days agoSarepta Therapeutics, a Cambridge drugmaker known for its Duchenne muscular dystrophy treatments,...